EPS Q/Q společnosti Inhibrx

Jaká je hodnota metriky EPS Q/Q společnosti Inhibrx?

Hodnota metriky EPS Q/Q společnosti Inhibrx, Inc. je 66.67%

Jaká je definice metriky EPS Q/Q?



Čtvrtletní růst EPS (Quarterly EPS growth rate) ze čtvrtletí na čtvrtletí, je nárůst EPS společnosti za poslední čtyři čtvrtletí v porovnání s výsledky z minulých čtyř čtvrtletí.

The earnings per share growth rate is an important factor for judging a company's value. EPS growth rate gives a good picture of the rate at which the company has grown its profitability in respect to the total number of shares. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

EPS Q/Q společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Inhibrx

Čemu se věnuje společnost Inhibrx?

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Firmy s metrikou eps q/q podobnou společnosti Inhibrx